gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · BBNXHealthcareSurgical Instruments

Beta Bionics, Inc. Common Stock (BBNX)

$16.95+12.25%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$15.10▼ 45.50% in range
Nov 3, 2025Low $8.86 · High $31.99Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Beta Bionics closed at $16.95 on Nov 4, up 12.25%, 47.0% below its 52-week closing high. Volume of 1.2M shares was 1.00× its 20-day average (close to normal).

Split-adjusted performance: -9.0% over one month, +60.4% over six months, -38.8% over one year.

In the quarter ended Sep 30, 2026, revenue was $35.51M, up 30.3% from a year earlier, with a net margin of -68.6%.

Short interest was 6.9M shares at the Oct 15 settlement, up 14.4% from the prior report (24.4% of float, 7.4 days to cover).

Market cap$921.5M54.4M shares
Revenue · quarter$35.5M+30.3% YoY
Diluted EPS$-0.52—
P/E · TTM—P/S 7.2×
Net margin-68.6%Gross 57.3%
Dividend yieldNone
52-week range8.86 – 31.99−47.0% from high
Volume1.2M1.00× 20-day avg
Volatility · 60d81.7%Annualised
Short % of float24.4%7.4 days to cover
Net cash$240.2MCash $240.2M
Next earnings—Not scheduled
Split-adjusted performance
1W −5.0%1M −9.0%3M +20.1%6M +60.4%YTD −44.4%1Y −38.8%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Surgical Instruments

Percentile among 110 companies (100 = best)

6-month momentum87
Revenue growth86
Net margin27
Value (low P/E)—
Size67

Industry medians: 6-month return −4.0%, revenue growth +8.9%, net margin −8.2%, P/E 30.5×.

Short interest

Details →
Shares short6.9M+14.4% vs prior
Days to cover7.4Settled Oct 15
% of float24.4%
Short vol. 10d61.1%of daily volume

Closest peers by size in Surgical Instruments

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
BBNXBeta Bionics$16.95+12.25%+60.4%+30.3%−68.6%—$921.5M
KIDSOrthoPediatrics$33.51+6.69%+95.7%+18.6%−8.2%—$875.0MCompare
BVSBioventus$11.42+4.34%+4.6%+2.7%4.2%13.0$780.0MCompare
SIBNSI-BONE$24.95+4.96%+92.1%+15.2%−7.3%—$1.12BCompare
IRMDiRadimed$88.58+9.21%+2.7%+14.2%26.9%47.2$1.13BCompare
SGPSpyGlass Pharma$34.450.00%+37.5%———$1.15BCompare
IARTIntegra LifeSciences$14.82+8.73%+5.9%+2.3%3.6%88.6$1.15BCompare
PRCTPROCEPT BioRobotics$21.66+7.39%−12.7%+19.3%−28.4%—$1.24BCompare
ATECAlphatec Holdings$8.28+10.84%+18.5%+12.6%−2.5%—$1.27BCompare

News about Beta Bionics

All news →
BBNX FINAL DEADLINE: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important November 3 Deadline in Securities Class Action - BBNXGlobeNewswire Inc. · 2d ago▼ NegativeDeadline Alert: Beta Bionics, Inc. Investors Have Until November 3, 2026 to Seek Lead Plaintiff Role in Securities Fraud Class Action, Glancy Prongay Wolke & Rotter LLP Reminds InvestorsGlobeNewswire Inc. · 2d ago▼ NegativeBronstein, Gewirtz & Grossman LLC Urges Beta Bionics, Inc. Investors to Act: Class Action Filed Alleging Investor HarmGlobeNewswire Inc. · 3d ago▼ NegativeBBNX DEADLINE TUESDAY: Bragar Eagel & Squire, P.C. Reminds Beta Bionics, Inc. Investors They Have Until November 3rd to Seek Lead Plaintiff Role with the FirmGlobeNewswire Inc. · 4d ago▼ NegativeKaplan Fox Alerts Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to an Upcoming Deadline of November 3, 2026 in the Securities Class ActionGlobeNewswire Inc. · 5d ago▼ Negative

Quick answers

What does Beta Bionics do?
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet).
What is BBNX's market cap?
$921.52M, based on the Nov 4 close of $16.95.
Does Beta Bionics pay a dividend?
No regular cash dividend has been paid in the last year.
How much of BBNX is sold short?
6.9M shares, 24.4% of float, as of Oct 15, 2026.
What sector is BBNX in?
Healthcare, in the Surgical Instruments industry.

About Beta Bionics

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

HQ: Irvine, CA423 employeesListed Jan 30, 2025betabionics.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology